Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
Gut, 2006 - gut.bmj.com
Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation
of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised …
of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised …
[引用][C] Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Štimac… - Gut, 2006 - elibrary.ru
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Štimac… - Gut, 2006 - croris.hr
Sažetak INTRODUCTION: Interferon gamma is a potent proinflammatory cytokine implicated
in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of …
in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of …
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
DW Hommes, TL Mikhajlova, S Stoinov, D Stimac… - Gut, 2006 - europepmc.org
Methods A total of 133 patients with Crohn's disease activity index (CDAI) scores between
250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg …
250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg …
[HTML][HTML] Fontolizumab, a humanised anti‐interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Štimac… - Gut, 2006 - ncbi.nlm.nih.gov
Methods A total of 133 patients with Crohn's disease activity index (CDAI) scores between
250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg …
250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg …
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Stimac… - Gut, 2006 - pubmed.ncbi.nlm.nih.gov
Introduction Interferon gamma is a potent proinflammatory cytokine implicated in the
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …
Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Štimac… - Gut, 2006 - gut.bmj.com
Abbreviations: CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; CRP, C-reactive
protein; DSMB, Data Safety Monitoring Board; ELISA, enzyme-linked immunosorbent assay; …
protein; DSMB, Data Safety Monitoring Board; ELISA, enzyme-linked immunosorbent assay; …
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov… - Gut, 2006 - researchinformation.amsterdamumc …
INTRODUCTION: Interferon gamma is a potent proinflammatory cytokine implicated in the
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …
[PDF][PDF] Fontolizumab, a humanised anti-interferon c antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Štimac… - Gut, 2006 - researchgate.net
Results: There was no statistically significant difference in the primary end point of the study
(clinical response) between the fontolizumab and placebo groups after a single dose at day …
(clinical response) between the fontolizumab and placebo groups after a single dose at day …
Fontolizumab, a humanised anti-interferon [GAMMA] antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
DW Hommes, TL Mikhajlova, S Stoinov, D Stimac… - Gut, 2006 - search.proquest.com
Introduction: Interferon [GAMMA] is a potent proinflammatory cytokine implicated in the
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …
inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab …